Table 3.
Keyword search and MeSH terms used for Ovid medline for the present scoping review
| 1. | Hyaluronic acid/ |
| 2. | Cosmetic techniques/ |
| 3. | Dermal fillers/ |
| 4. | Injections, subcutaneous/ |
| 5. | (Hyaluronic Acid or Hyaluronoglucosaminidase or HA filler* or cosmetic techniq* or dermal filler*).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword heading word, floating subheading word, candidate term word] |
| 6. | 1 or 2 or 3 or 4 or 5 |
| 7. | Postoperative complications/ |
| 8. | Injections, intra. arterial/ |
| 9. | Vascular diseases/ |
| 10. | Inflammation/ |
| 11. | Vasculitis, Leukocytoclastic, Cutaneous/ |
| 12. | Drug hypersensitivity/ |
| 13. | Hypersensitivity, delayed/ |
| 14. | Hypersensitivity/ |
| 15. | Eye pain/ |
| 16. | Chronic pain/ |
| 17. | Pain/ |
| 18. | Skin diseases, viral/ |
| 19. | Skin diseases, bacterial/ |
| 20. | Skin.mp. and connective tissue diseases/[mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword heading word, floating subheading word, candidate term word] |
| 21. | Skin diseases, eczematous/ |
| 22. | Skin diseases, Papulosquamous/ |
| 23. | Skin diseases, vascular/ |
| 24. | Ecchymosis/ |
| 25. | Ischemic stroke/ |
| 26. | Edema/ |
| 27. | Intracranial Embolism.mp. and Thrombosis/[mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword heading word, floating subheading word, candidate term word] |
| 28. | Embolism.mp. and Thrombosis/[mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword heading word, floating subheading word, candidate term word] |
| 29. | Intracranial embolism/ |
| 30. | Embolism/ |
| 31. | Blindness/ |
| 32. | Visual acuity/ |
| 33. | (adverse effect* or nodule* or papule* or mass* or lump* or bump* or induration* or granuloma* or granulation tissue* or foreign bod* or hypersensitivit* or swelling* or inflammation* or thrombosis or ischemia or embolism* or vascular embolism* or vascular occlusion* or necrosis or blindness or dermatosis or adverse event* or complication*).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword heading word, floating subheading word, candidate term word] |
| 34. | 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 |
| 35. | Hyaluronoglucosaminidase/ |
| 36. | Thrombolytic therapy/ |
| 37. | (Hyaluronidase or HYAL or Hylenex or Hydase or Vitrase or Wydase or Hyalase).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword heading word, floating subheading word, candidate term word] |
| 38. | 35 or 36 or 37 |
| 39. | Retrospective studies/ |
| 40. | Case. Control studies/ |
| 41. | Follow. Up studies/ |
| 42. | Prospective studies/ |
| 43. | (RCT or Randomi#ed clinical trial* or clinical trial* or retrospective stud* or Case. Control stud* or Case control Stud*).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword heading word, floating subheading word, candidate term word] |
| 44. | 39 or 40 or 41 or 42 or 43 |
| 45. | 6 and 34 and 38 and 44 |